POSTDOCTORAL POSITION for the RESHAPE EU 2020 program

We recruitThe research activity will take place in a strong research environment within Team 2 of INSERM UMR 1064-Center for Research in Transplantation and Immunology (CRTI)  led by Carole Guillonneau and Ignacio Anegon and under their direct supervision. The topic will be the genome editing of CD8+ Treg cells and their application to in vitro suppression assays (suppression of MLRs) and animal models (immune humanized NSG mice) of GVHD and human skin transplantation. This project will be performed in the context of an European Union H2020 project with nine European partners (Charité-Berlin, Oxford University…) in which the main objective is to generate next-generation Treg products (CAR Treg, more stable Treg, more potent Treg, etc) to apply in patients with organ transplantation or autoimmune diseases. For more information, job profile.

LabEx IGO : 5-year renewal


logo labex igo

Certified in 2012 as part of the PIA program, the LabEx Immunotherapy-Graft-Oncology (IGO) has just been extended for 5 years (2020-2024) following an evaluation by an international jury, based on its scientific results and the impact of its activities on the structuring of immunology teams in the French large-western region. From January 1st 2020, Ignacio Anegon (CRTI) and Nathalie Labarrière (CRCINA), current scientific director and deputy scientific director of LabEx IGO, will be replaced by Emmanuel Scotet (CRCINA) and Régis Josien (CRTI). Composed of teams 1, 2, 3 and 4 of the UMR1064-CRTI Nantes, teams 1, 2, 3, 4, 7, 9 and 13 of UMR1232-CRCINA Nantes-Angers, UMR1236-MICMAC Rennes and of the UMR1227-LBAI Brest, the LabEx IGO 2020 will host two new teams: team 5 of UMR1232-CRCINA led by F. Altare "microbiota and cancer" and team 5 of UMR1064-CRTI led by PA Gourraud "Immunogenomics in transplantation and autoimmunity", strengthening the structuring effect of this program. The LabEx IGO 2020 follows on from the programs developed between 2012 and 2019 and will focus on 3 specific research axes (Immune regulation and new therapeutic targets, Innovative immunotherapies and combined strategies, Immunological markers associated with therapeutic responses) in order to keep implementing ambitious and transdisciplinary collaborative projects in the areas of immuno-oncology, immuno-transplantation and autoimmunity. The LabEx IGO 2020 also aims at promoting technological developments enabling high content analyses of the immune system 1) by imaging: acquisition of an Akoya CoDEX in Nantes (25 markers) and a Hyperion Fluidigm in Brest (50 markers) and 2) by cytometry: acquisition of a high-content analyser cytometer allowing the simultaneous analysis of more than 35 fluorescent markers in Nantes.

Restore Health – Therapies that cure. A project funded with 1 million euros to obtain 1 billion euros

RESTOREShifting from treating symptoms to curing diseases and making Europe the world leader in Advanced Therapies is the aspiration of RESTORE – the Large-Scale Research Initiative, led by Charité and Berlin Institute of Health (BIH). On Febr. 09, 2019, the European Commission (EC) backed that vision and announced that RESTORE will receive initial funding of EUR 1 Million, and invited the consortium to develop fully their concept and to expand further the community that strives to propel Europe to the forefront in Advanced Therapies. For more information, please download the press release.

Webinar sur le séquençage de TCR

Webinar sponsorisé par Qiagen sur le séquençage de TCR (Nathalie Labarrière)
Webinar N. Labarrière

Last publications

Journal of Immunology

Glatiramer Acetate Stimulates Regulatory B Cell Functions

Amrouche K, Pers JO, Jamin C

J Immunol. 2019 Feb 11 - Download full text

onco immuno

The regulatory capacity of B cells directs the aggressiveness of CLL

Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C

Oncoimmunology. 2018 Dec 12;8(3):1554968

frontiers

CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients

Brosseau C, Durand M, Colas L, Durand E, Foureau A, Cheminant MA, Bouchaud G, Castan L, Klein M, Magnan A, Brouard S

Front Immunol. 2018 Dec 21;9:3034 - Download full text

frontiers

TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features

Simon S, Wu Z, Cruard J, Vignard V, Fortun A, Khammari A, Dreno B, Lang F, Rulli SJ, Labarriere N

Front Immunol. 2018 Aug 30;9:1962 - Download full text

J IMMUNO

IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors

Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E

J Immunother. 2018 Jun;41(5):224-231

Seminars

Aix MarseillePaul Pascale

Evaluation de l'alloactivité humorale des cellules Natural Killer chez les patients transplantés d'organe

Centre de recherche en cardiovasculaire et nutrition, C2VN, INSERM 1263, Aix Marseille Université
27 février, 2019, 14h30 - Amphi. D. Escande

Media

Mélanome : les promesses de l’immunothérapie

Booster le système immunitaire des patients pour les aider à lutter eux-mêmes contre leur cancer ! Telle est la mission de l'immunothérapie. Travaillant depuis 25 ans sur le sujet et notamment sur le mélanome, une équipe de recherche du Centre Régional de Recherche en Cancérologie Nantes-Angers (CRCNA) étudie les spécificités et les fonctions d'un nouveau type de lymphocytes T, appelés lymphocytes T double-positifs, qu'elle a découvert en 2009 dans des mélanomes de stade avancé. Ces lymphocytes T sont-ils des alliés contre cette tumeur ? Comment l'équipe procède-t-elle pour le savoir ? Suivez pas à pas leurs recherches et leurs premiers résultats. Ce film a été réalisé grâce au soutien de la Région Pays de la Loire sur le projet "Impact des lymphocytes T αβ double positifs CD4+CD8+ intra-tumoraux sur la réponse immune anti-mélanome »